Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Oct
29
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo